Diagnostic and prognostic utility of PSMA ‐ PET / CT in node‐metastatic prostate cancer
BJU International · 2026-08 · 138 (2) · 250-256
DOI: 10.1111/bju.70280 ↗Kurz gefasst
Fachartikel in der Zeitschrift BJU International, online erschienen am 30.04.2026. Verfasst von Nicholas A Pickersgill und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery (Urology Service), Memorial Sloan Kettering Cancer Center, New York, NY, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Positron Emission Tomography Computed Tomography, Lymphatic Metastasis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Sidney Kimmel Center for Prostate and Urologic Cancers at MSKCC and NIH/NCI.
Abstract (Originalsprache)
Objective
To measure the sensitivity of prostate‐specific membrane antigen‐positron emission tomography/computed tomography (PSMA‐PET/CT) for detecting lymph node involvement (LNI) in patients undergoing radical prostatectomy (RP) and extended pelvic lymph node dissection (PLND) and to evaluate whether PSMA nodal status independently predicts oncological outcomes. Patients and Methods We identified patients with localised or locoregional prostate cancer who underwent PSMA‐PET/CT followed by RP (2021–2024) at a high‐volume centre and had pathologically confirmed LNI (pN1) on PLND. We evaluated the sensitivity of PSMA‐PET/CT for detecting pN1 disease. Associations between PSMA‐PET/CT and biochemical recurrence (BCR), any radiographic recurrence, and distant recurrence were evaluated using Cox regression models.
Results
Overall, PSMA‐PET/CT detected LNI in 24 of 79 patients with pN1 disease, a sensitivity of 30% (95% confidence interval [CI] 21–42%). PSMA‐positive nodal disease (clinical N1 [cN1]) was significantly associated with BCR (hazard ratio [HR] 2.34, 95% CI 1.26–4.36; P = 0.009), radiographic recurrence (HR 4.23, 95% CI 1.86–9.58; P < 0.001), and distant radiographic recurrence (HR 5.81, 95% CI 1.79–18.8; P = 0.002). The 1‐year risk of BCR approached 90% for those with cN1 disease. Median metastatic focus size was larger in cN1 vs cN0 patients (1.1 vs 0.3 cm; P < 0.001). Limitations include relatively short follow‐up.
Conclusions
Due to low sensitivity, PSMA‐PET/CT without evidence of nodal disease does not obviate the need for PLND. However, PSMA‐avid nodal disease portends a nearly inevitable short interval recurrence and radiographic progression, supporting treatment intensification.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery (Urology Service), Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
ORCID-Profile: Behfar Ehdaie, Andrew J Vickers, Christoper D Gaffney
Förderung
- NCI NIH HHS
- Sidney Kimmel Center for Prostate and Urologic Cancers at MSKCC and NIH/NCI
Zitieren
APA
Pickersgill, N. A., Yu, R., Vertosick, E. A., Fletcher, S. A., Liso, N., Kluckert, J., Akin, O., Ehdaie, B., Laudone, V. P., Eastham, J. A., Vickers, A. J., Touijer, K. A., & Gaffney, C. D. (2026). Diagnostic and prognostic utility of PSMA ‐ PET / CT in node‐metastatic prostate cancer. BJU International, 138(2), 250-256. https://doi.org/10.1111/bju.70280
Vancouver
Pickersgill NA, Yu R, Vertosick EA, Fletcher SA, Liso N, Kluckert J, et al. Diagnostic and prognostic utility of PSMA ‐ PET / CT in node‐metastatic prostate cancer. BJU International. 2026;138(2):250-256. doi:10.1111/bju.70280
BibTeX
@article{Pickersgill2026,
author = {Pickersgill, Nicholas A and Yu, Rebecca and Vertosick, Emily A and Fletcher, Sean A and Liso, Nicole and Kluckert, Jonas and Akin, Oguz and Ehdaie, Behfar and Laudone, Vincent P and Eastham, James A and Vickers, Andrew J and Touijer, Karim A and Gaffney, Christoper D},
title = {Diagnostic and prognostic utility of PSMA ‐ PET / CT in node‐metastatic prostate cancer},
journal = {BJU International},
year = {2026},
volume = {138},
number = {2},
pages = {250--256},
doi = {10.1111/bju.70280}
}
EUVIMED